The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Costa R, Costa-Filho RB, Talamantes SM, Queiroga F Jr, Campello EC, Cartaxo H, Costa RB

Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review.

Case reports in oncology. 2017;10(2):524-530

Abulkhair O, El Melouk W

Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.

Case reports in oncology. 2011;4(1):186-91

Ahamed E, Mauri FA, Pakter G, Lim A, Stebbing J

Trastuzumab: unusual responses and toxicities.

Future oncology (London, England). 2009;5(6):779-84

Bettini AC, Tondini C, Poletti P, Caremoli ER, Guerra U, Labianca R

A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab.

Tumori. 2008;94(5):737-41

González V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G

Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.

Pharmacoepidemiology and drug safety. 2008;17(7):714-21